Prescribing overview
The reviewed prescription clemastine tablet label is for humans; historical Tavist identity does not establish animal approval.
Key prescribing checks
- Human information includes drowsiness, impaired coordination and anticholinergic effects such as dryness and difficulty urinating. Species-specific prescribing needs veterinary assessment.
- Review other sedating drugs, monoamine oxidase inhibitors and conditions such as glaucoma or urinary difficulty before considering use.
- A human brand match does not authorize an animal dose or establish that a decongestant-containing product is suitable for a pet. Confirm formulation instead of relying on a familiar allergy brand name.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Humans; animal use not verified
Human prescription labelingAllergic rhinitis and uncomplicated urticaria/angioedema
No veterinary indication or regimen established here.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Competes with histamine at receptor sites; sedative and anticholinergic effects accompany antihistaminic action.
Absorption, distribution, metabolism and elimination
Human studies report rapid gastrointestinal absorption, peak concentrations at 2–4 hours and predominantly urinary elimination. These values must not be extrapolated to animals.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Tavist / Tavist Allergy / Tavist-1
Historical human clemastine brands; restrictions below derive from the reviewed prescription clemastine tablet label, not a verified current package for each historical brand.
Contraindications · when not to use
- Human label excludes nursing mothers, hypersensitivity to clemastine or chemically similar antihistamines, and MAO-inhibitor therapy; antihistamines should not treat lower-respiratory symptoms including asthma.
Precautions & monitoring
- Caution with narrow-angle glaucoma, gastrointestinal obstruction/stenosing ulcer, prostate or bladder-neck obstruction, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypotension. Pregnancy data are inadequate; sedation can occur.
Exact historical brand package needs confirmation; Tavist-D combination products are outside this scope. Human restrictions are not automatically veterinary contraindications.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Human experience includes frequent transient drowsiness, dryness, disturbed coordination and urinary difficulty.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
Veterinary dose not verified; human dosing omitted.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Tavist / Tavist Allergy / Tavist-1
Historical human clemastine brands; restrictions below derive from the reviewed prescription clemastine tablet label, not a verified current package for each historical brand.
- MAO inhibitors intensify anticholinergic effects. Alcohol and other CNS depressants add sedation.
Monitoring
Veterinarian should reconcile CNS depressants, MAO inhibitors and relevant ocular or urinary disease.
Client counseling
Confirm the ingredient panel; combination allergy products are not equivalent to plain clemastine.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Reviewed tablets: 20–25°C in a tight, light-resistant container.
Brands, formulations & ingredient identity
Active ingredients
Clemastine
Other searchable names: clemastine fumarate · clemastine hydrogen fumarate
Tavist Allergy was formerly called Tavist-1. These names are useful historical brand matches, and availability should be checked locally.
Tavist-D is a combination-family name and must not be collapsed into clemastine alone. Check every active ingredient on the actual package.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Tavist
- Formulation
- Human oral tablet
- Label / product scope
- Human product
Historical brand identity; local availability varies.
Product label / source ↗Tavist Allergy
- Formulation
- Human oral tablet
- Label / product scope
- Human product
Formerly Tavist-1; exclude combination variants.
Product label / source ↗Tavist-1
- Formulation
- Human oral tablet
- Label / product scope
- Human product
Former name for Tavist Allergy.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.